Compare Abbott Laboratories (ABT) vs Eni SpA (E) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Eni SpA — how do they compare? Abbott Laboratories trades at $95.78 (market cap $166.94B), while Eni SpA trades at $48.39 (market cap $67.72B). The key difference: Abbott Laboratories is far larger — about 2.5× Eni SpA's market cap, and Eni SpA pays the higher dividend (5.25%). Which is the better fit depends on your goals.
| ABT | E | |
|---|---|---|
Market Cap | $166.94B | $67.72B |
Sector | Health | Energy |
52-Week High | $136.62 | $57.61 |
52-Week Low | $82.57 | $32.93 |
Enterprise Value | $193.69B | $86.63B |
Dividend Yield | 2.63% | 5.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Eni (E) trades at $47.47, up 1.28% with a bearish technical signal despite recent earnings beats. The company shows stable cash flow generation with $13.33B operating cash flow in 2025 and maintains a reasonable valuation with P/E of 20.51 and P/S of 0.75. Recent strategic moves include lithium investments in Chile and fusion energy partnerships, signaling diversification beyond traditional energy operations.
While analyst consensus leans neutral (61.53% hold), Eni's transition strategy and global expansion present long-term opportunities. Key risks include declining revenue trends from $132.5B in 2022 to $82.15B in 2025 and competitive pressures in the energy sector. The stock offers value characteristics with dividend income potential amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →
